RJF — Raymond James Financial, Inc.

As of 2026-09-13 the tape is cooling but not broken: RJF is down 4.26% over one month and 2.71% over one week, yet up 12.34% over three months and 18.83% over six. Sell-side is genuinely mixed - a Hold consensus with a 1/11/14/0/0 strong-buy/buy/hold/sell/strong-sell split and a consensus target of $177.33 (recent average $183.20, range $160-$188), so the Street sees only ~2-6% upside from $173.46. The bullish case rests on operating momentum (client assets ~$1.93T in July 2026, AUM $344.6B, bank loans $56.3B, continued wirehouse advisor recruiting) and a dividend of $0.54/quarter declared August 26, 2026; the cautious case rests on the pending interest-rate easing cycle compressing net interest income on client cash sweeps.

The three-year revenue series inflects rather than drifts. Revenue ran $3,474M (Sep-23) to $3,982M (Dec-24), then dipped to $3,791M (Mar-25) and $3,786M (Jun-25) before re-accelerating to record sequential highs of $4,130M (Sep-25), $4,176M (Dec-25), $4,262M (Mar-26) and $4,362M (Jun-26). YoY growth went 4.5% (Sep-25), 4.9% (Dec-25), 12.4% (Mar-26), 15.2% (Jun-26) - a clear acceleration, not a blip. The mid-2025 softness was an earnings/margin event, not a revenue event: operating margin fell to 14.9% in Jun-25 (operating income $563M) versus 19.2% in Sep-24 and 18.8% in Dec-24, then recovered to 17.7%/17.4%/17.2%/17.2% across the last four quarters while net income jumped to $595M in Jun-26 (+36.5% YoY) and diluted EPS to $3.01 (from $2.12). Margins have stabilized around 17%, still ~200bp below the Sep-24 peak, so the story is 'recovered and re-accelerating,' with further margin recapture as the remaining upside rather than a structural decline.

Fairly valued to modestly rich versus its own history. As of 2026-09-13, the TTM P/E of 14.84 sits ~8.6% above the 5-year average of 13.67, and P/S of 1.968 sits ~5.2% above the 5-year average of 1.87 - so the deterministic score's 'Neutral vs. its own history' tag is right, leaning slightly to the rich side. On forward numbers the picture softens: $173.46 / $12.151 next-FY EPS = 14.28x, only slightly above the historical average. PEG of 1.239 looks expensive only because consensus EPS growth is thin (~2-5% off a $11.89 TTM base), which is the real valuation tension: you are paying a low-teens multiple for low-single-digit EPS growth. Supporting the multiple are 17.1% ROE, 15.9% ROIC, 13.6% net margin, a 1.34% dividend yield and a 2.65x P/B that is rich for a broker but reasonable for a wealth-management compounder.

The market has already paid for the re-acceleration that showed up in the numbers: +12.34% over three months and +18.83% over six months against revenue growth of 12-15% YoY. The risk now is that price is discounting a continuation the consensus EPS line does not show - analysts model next-FY EPS of $12.151, only ~2% above the $11.887 TTM figure, which implicitly assumes rate-cut NII pressure and/or expense growth eats the revenue upside. Read it this way: if the Oct-28-2026 fiscal Q4 print shows 17%+ operating margins holding and net new assets staying strong, the $12.15 estimate likely proves too low and the multiple is justified; if NII rolls over faster than fees grow, a low-teens multiple on a no-growth EPS number leaves little cushion from $173.46.

Neutral-to-constructive consolidation. As of 2026-09-13, RSI(14) at 45.87 is dead-center - neither overbought nor oversold, and notably it is not confirming the recent pullback as a breakdown. Price is 1.85% below the 20-day SMA and 0.38% below the 50-day SMA, i.e. short-term chop, but 7.91% above the 200-day SMA, meaning the primary trend is still up. The stock is also only ~5% below its 52-week high of $182.73 and 25% above the low of $138.82. Entry-timing implication: there is no urgency here - this is a 'buy the 200-day test, not the 20-day drift' setup. A push back above the 20/50-day cluster would confirm the uptrend; a deeper slide toward the 200-day would be the more attractive risk/reward entry.

• Interest-rate easing cycle: net interest income and client cash sweep balances are the most rate-sensitive part of the model, and falling short rates compress the spread RJF earns on client cash, directly threatening the NII leg that helped drive the 2024 peak margins.
• Capital-markets recovery: underwriting and advisory revenue is levered to M&A pipelines and equity issuance; a sustained reopening of capital markets is the clearest offset to NII pressure and a reason the Capital Markets segment could surprise upward.
• Equity market levels: roughly 60% of client assets sit in fee-based accounts, so asset-based advisory fees scale with market levels - a broad drawdown would hit revenue faster than expenses can adjust.
• Regulatory scrutiny: ongoing SEC/FINRA attention to sweep-account yields, AML programs and broker-dealer compliance keeps a structural cost and headline-risk overhang on the independent broker-dealer model.
• Wealth-management competition for advisors: wirehouse recruiting remains intense, and the economics of recruiting deals (upfront notes, retention) are a persistent drag on near-term margins even when headcount growth is strong.

• Fiscal Q4 and full-year FY2026 results on October 28, 2026 - the key read on expense management, advisor productivity and whether ~17% operating margins hold as rates fall.
• Monthly operating disclosures (client assets, net new assets, advisor headcount) - July 2026 already showed ~$1.93T client assets, $344.6B AUM and $56.3B net bank loans, and continued strength would validate the forward EPS estimate as conservative.
• Continued capital-markets recovery lifting the underwriting/advisory segment, which is the highest-incremental-margin offset to NII compression.
• Capital return: the $0.54/quarter dividend declared August 26, 2026 (payable October 15, 2026) plus any incremental buyback, against only $3.5B of long-term debt (down from $4.22B in Dec-25) on $12.7B of equity.
• Clarity on the Fed path and the resulting reset of expectations for client cash sorting and sweep yields.

• Rate-cut-driven NII compression: sweep and cash-balance economics are the single biggest swing factor, and the consensus EPS line of $12.151 already looks like it embeds some of this - the risk is that it is under-embedded.
• A meaningful equity-market drawdown would hit asset-based fees, net new asset flows and capital-markets activity simultaneously - the correlation risk of a wealth manager.
• Margin recapture stalling below the Sep-24 peak of 19.2%: four straight quarters at 17.2-17.7% suggest the expense base has reset structurally higher, not just cyclically.
• Advisor attrition or a slowdown in recruiting would undermine the organic-growth engine that justifies a premium to the historical multiple.
• Regulatory/legal outcomes on sweep yields or AML compliance could force both remediation costs and business-model changes.
• Valuation risk: at 14.84x TTM and 2.65x book, RJF is priced above its own 5-year average with only low-single-digit consensus EPS growth to support it.

RJF is a genuinely high-quality wealth manager - ~$1.93T in client assets, 17.1% ROE, 15.9% ROIC, a 0.01% accruals ratio that says reported earnings are backed by real cash, conservative balance-sheet leverage, and revenue that has re-accelerated from ~4.5% YoY in mid-2025 to 15.2% in Jun-2026. The problem is price, not quality: at $173.46 as of 2026-09-13 the stock trades above its 5-year average P/E and P/S with consensus forward EPS growth of only ~2-5%, and the interest-rate easing cycle is a direct headwind to the NII that powered the 2024 margin peak. This is a decent business at a full-ish price - own it on weakness toward the 200-day, not here.

Forward P/E on consensus next-fiscal-year EPS: I applied 14.7x to the $12.151 next-FY EPS estimate, giving $178.60. The multiple sits just above RJF's 5-year average P/E of 13.67x and just below its TTM P/E of 14.84x as of 2026-09-13 - a modest premium justified by accelerating revenue (+15.2% YoY in Jun-26), 17.1% ROE, a 0.01% accruals ratio and a strong net-new-asset/advisor-recruiting engine, tempered by the rate-cut NII headwind that keeps forward EPS growth in the low single digits. Cross-check: 2.7x book on ~$66 BVPS lands near $178, and it sits within the sell-side $160-$188 target range without simply copying the $177.33 consensus.